Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review.


Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
02 2021
Historique:
received: 19 10 2019
revised: 21 07 2020
accepted: 27 07 2020
pubmed: 9 8 2020
medline: 31 7 2021
entrez: 9 8 2020
Statut: ppublish

Résumé

Systematic review of risk factors for nonadherence and nonpersistence to intravitreal anti-vascular endothelial growth factor (VEGF) injection therapy for neovascular age-related macular degeneration (nAMD). Lack of adherence (nonadherence) or undertreatment (nonpersistence) with respect to evidence from clinical trials remains a significant barrier to optimizing real-world outcomes for patients with nAMD. Contributing factors and strategies to address this are poorly understood. Studies that reported factors for nonadherence and nonpersistence to anti-VEGF therapy as well as studies examining strategies to improve this were included. Trial eligibility and data extraction were conducted according to Cochrane review methods. Risk of bias was assessed using the Mixed Method Assessment Tool and certainty of evidence evaluated according to the GRADE Confidence in the Evidence from Reviews of Qualitative Research tool. Data were collated descriptively. Of the 1284 abstract results screened, 124 articles were assessed in full and 37 studies met the inclusion criteria. Definitions of nonadherence and nonpersistence varied or were not reported. Nonpersistence occurred early, with up to 50% of patients stopping treatment by 24 months. High rates of nonadherence were similarly reported, occurring in 32% to 95% of patients. Certainty of this finding was downgraded to a moderate level because of the heterogeneity in definitions used across studies. Multiple factors determine nonadherence and nonpersistence, including at the condition, therapy, patient, social/economic, and health systems/healthcare team levels. Moderate quality evidence points to lower baseline vision and poorer response to treatment as condition-related variables. The effects of other factors were of lower certainty, predominantly due to small numbers and potential biases in retrospective assessment. Although many factors are not modifiable (e.g., patient comorbidity), other factors are potentially correctable (e.g., lack of transport or mismatched patient expectations). Evidence on strategies to improve adherence and persistence is limited, but where available, these have proven effective. Awareness of factors related to poor patient adherence and persistence in nAMD could help identify at-risk populations and improve real-world outcomes. Further work is required to develop uniform definitions and establish high-quality evidence on interventions that can be easily implemented.

Identifiants

pubmed: 32763265
pii: S0161-6420(20)30748-X
doi: 10.1016/j.ophtha.2020.07.060
pmc: PMC7403101
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

234-247

Informations de copyright

Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Références

Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2119-2125
pubmed: 31286206
Retina. 2017 Dec;37(12):2254-2261
pubmed: 28092343
Retina. 2016 Aug;36(8):1418-31
pubmed: 27388744
Psychol Health Med. 2018 Feb;23(2):127-140
pubmed: 28064517
Lancet. 2018 Sep 29;392(10153):1147-1159
pubmed: 30303083
Am J Ophthalmol. 2014 Sep;158(3):537-43.e2
pubmed: 24857687
Clin Ophthalmol. 2016 Dec 15;10:2505-2513
pubmed: 28008223
Ophthalmologe. 2018 Dec;115(12):1035-1041
pubmed: 29138977
Am J Ophthalmol. 2012 Jun;153(6):1116-24.e1
pubmed: 22321802
Graefes Arch Clin Exp Ophthalmol. 2013 May;251(5):1281-4
pubmed: 23086225
J Ophthalmol. 2017;2017:7194927
pubmed: 28660080
JAMA Ophthalmol. 2018 Nov 1;136(11):1251-1259
pubmed: 30352121
Ophthalmology. 2009 Nov;116(11 Suppl):S43-7
pubmed: 19837260
Psychol Health Med. 2015;20(3):296-310
pubmed: 25034616
Br J Ophthalmol. 2020 Nov;104(11):1573-1578
pubmed: 32066561
Ophthalmology. 2009 Nov;116(11 Suppl):S37-42
pubmed: 19837259
Cochrane Database Syst Rev. 2019 Mar 04;3:CD005139
pubmed: 30834517
J Fr Ophtalmol. 2017 Oct;40(8):642-647
pubmed: 28865938
J Fr Ophtalmol. 2015 Sep;38(7):620-7
pubmed: 25913443
Acta Ophthalmol. 2017 Mar;95(2):128-132
pubmed: 27535819
Clin Exp Ophthalmol. 2018 May;46(4):407-411
pubmed: 29044979
Klin Monbl Augenheilkd. 2013 Dec;230(12):1251-6
pubmed: 24327288
PLoS One. 2017 Dec 8;12(12):e0189035
pubmed: 29220371
Eye (Lond). 2015 Nov;29(11):1453-7
pubmed: 26206530
Turk J Ophthalmol. 2017 Aug;47(4):205-210
pubmed: 28845324
Ophthalmology. 2019 Jan;126(1):55-63
pubmed: 30077616
Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1873-1880
pubmed: 27262729
Arq Bras Oftalmol. 2010 Mar-Apr;73(2):146-9
pubmed: 20549043
Eye (Lond). 2018 Apr;32(4):673-678
pubmed: 29219960
Clin Ophthalmol. 2018 Dec 04;12:2483-2491
pubmed: 30584267
Lancet. 2012 May 5;379(9827):1728-38
pubmed: 22559899
Diabetes Ther. 2019 Apr;10(2):437-449
pubmed: 30850934
Ophthalmologe. 2016 Nov;113(11):925-932
pubmed: 27272633
Ophthalmology. 2012 Dec;119(12):2537-48
pubmed: 23084240
Eur J Ophthalmol. 2011 Nov-Dec;21(6):777-82
pubmed: 21500186
Clin Ophthalmol. 2017 Dec 20;12:13-20
pubmed: 29339917
Br J Ophthalmol. 2015 Feb;99(2):220-6
pubmed: 25193672
JAMA Ophthalmol. 2020 Mar 1;138(3):237-242
pubmed: 32027349
Clin Ophthalmol. 2015 Dec 01;9:2243-50
pubmed: 26664038
J Ophthalmol. 2018 Apr 18;2018:4610129
pubmed: 29850205
Ophthalmic Epidemiol. 2018 Apr;25(2):176-182
pubmed: 29131696
Ophthalmology. 2013 Nov;120(11):2292-9
pubmed: 23642856
N Engl J Med. 2006 Oct 5;355(14):1432-44
pubmed: 17021319
Retina. 2018 Jun;38(6):1134-1144
pubmed: 28489692
Ophthalmology. 2015 Sep;122(9):1837-45
pubmed: 26096346
Diabetes Ther. 2013 Dec;4(2):175-94
pubmed: 23990497
Vestn Oftalmol. 2014 Jul-Aug;130(4):88-96
pubmed: 25306730
Retina. 2014 Sep;34(9):1774-8
pubmed: 24837049
Graefes Arch Clin Exp Ophthalmol. 2014 Jan;252(1):31-4
pubmed: 23860798
Am J Ophthalmol. 2013 Jan;155(1):89-95.e3
pubmed: 23022167

Auteurs

Mali Okada (M)

Royal Victorian Eye and Ear Hospital, Melbourne, Australia. Electronic address: Mali.Okada@eyeandear.org.au.

Paul Mitchell (P)

Department of Ophthalmology, University of Sydney, Sydney, Australia.

Robert P Finger (RP)

Department of Ophthalmology, University of Bonn, Bonn, Germany.

Bora Eldem (B)

Department of Ophthalmology, Hacettepe University, Ankara, Turkey.

S James Talks (SJ)

The Newcastle upon Tyne Hospitals NHS Foundation, Newcastle upon Tyne, United Kingdom.

Ceri Hirst (C)

Bayer Consumer Care, Basel, Switzerland.

Luciano Paladini (L)

Kantar Health Care, Sao Paulo, Brazil.

Jane Barratt (J)

International Federation on Ageing, Toronto, Canada.

Tien Yin Wong (TY)

Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore.

Anat Loewenstein (A)

Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH